The 36-month beta value for BTAI is also noteworthy at -0.00. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BTAI is 41.10M, and at present, short sellers hold a 2.56% of that float. The average trading volume of BTAI on January 06, 2025 was 668.81K shares.
BTAI) stock’s latest price update
The stock price of BioXcel Therapeutics Inc (NASDAQ: BTAI) has jumped by 24.64 compared to previous close of 0.41. Despite this, the company has seen a gain of 31.03% in its stock price over the last five trading days. zacks.com reported 2024-12-23 that BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BTAI’s Market Performance
BTAI’s stock has risen by 31.03% in the past week, with a monthly rise of 28.29% and a quarterly drop of -11.76%. The volatility ratio for the week is 12.99% while the volatility levels for the last 30 days are 15.13% for BioXcel Therapeutics Inc The simple moving average for the last 20 days is 30.45% for BTAI’s stock, with a simple moving average of -56.52% for the last 200 days.
Analysts’ Opinion of BTAI
Many brokerage firms have already submitted their reports for BTAI stocks, with UBS repeating the rating for BTAI by listing it as a “Neutral.” The predicted price for BTAI in the upcoming period, according to UBS is $4 based on the research report published on February 21, 2024 of the previous year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see BTAI reach a price target of $4, previously predicting the price at $40. The rating they have provided for BTAI stocks is “Neutral” according to the report published on August 15th, 2023.
BTAI Trading at 2.04% from the 50-Day Moving Average
After a stumble in the market that brought BTAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.63% of loss for the given period.
Volatility was left at 15.13%, however, over the last 30 days, the volatility rate increased by 12.99%, as shares surge +32.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.67% lower at present.
During the last 5 trading sessions, BTAI rose by +28.49%, which changed the moving average for the period of 200-days by -81.80% in comparison to the 20-day moving average, which settled at $0.3950. In addition, BioXcel Therapeutics Inc saw 38.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BTAI starting from O’Neill Vincent, who sale 165 shares at the price of $0.35 back on Dec 16 ’24. After this action, O’Neill Vincent now owns 19,957 shares of BioXcel Therapeutics Inc, valued at $58 using the latest closing price.
Mehta Vimal, the CEO and President of BioXcel Therapeutics Inc, sale 3,117 shares at $0.36 during a trade that took place back on Dec 16 ’24, which means that Mehta Vimal is holding 59,605 shares at $1,131 based on the most recent closing price.
Stock Fundamentals for BTAI
Current profitability levels for the company are sitting at:
- -32.96 for the present operating margin
- 0.04 for the gross margin
The net margin for BioXcel Therapeutics Inc stands at -31.19. The total capital return value is set at -3.21. Equity return is now at value -1766.94, with -95.08 for asset returns.
Based on BioXcel Therapeutics Inc (BTAI), the company’s capital structure generated 5.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.81. The debt to equity ratio resting at -1.22. The interest coverage ratio of the stock is -5.16.
Currently, EBITDA for the company is -165.42 million with net debt to EBITDA at -1.15. When we switch over and look at the enterprise to sales, we see a ratio of 40.14. The receivables turnover for the company is 758.67for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.87.
Conclusion
In summary, BioXcel Therapeutics Inc (BTAI) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
